Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Drug Overview

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (also known as MV-NIS) is an investigational, genetically engineered oncolytic virus derived from the Edmonston strain of the measles vaccine. This virus is specifically modified to selectively infect, replicate within, and destroy cancer cells while also carrying a “passenger gene” called the Sodium Iodide Symporter (NIS).

In the clinical landscape of March 2026, MV-NIS is recognized as a pioneer in “Theranostic Virotherapy.” Developed by researchers and licensed for various clinical trials, this virus serves a dual purpose: it acts as a biological weapon that physically ruptures tumor cells (oncolysis) and as a “tracking beacon.” By forcing the cancer cell to produce the NIS protein—which normally lives in the thyroid—the virus allows doctors to see exactly where the infection is located using standard medical imaging (PET or SPECT scans). This “live tracking” capability is a significant leap forward in ensuring that the virus is hitting its intended target in difficult-to-treat cancers like multiple myeloma and ovarian cancer.

• Generic Name: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter.
• Code Name: MV-NIS.
• Drug Class: Oncolytic Virotherapy; Gene Therapy; Theranostic Agent.
• Mechanism: Selective viral replication in CD46-overexpressing tumor cells leading to oncolysis, combined with NIS-mediated radiopharmaceutical uptake.
• Route of Administration: Intravenous (IV) infusion or Intraperitoneal (IP) injection.
• FDA Approval Status: Investigational. As of March 2026, MV-NIS is not FDA-approved. It has been granted Orphan Drug Designation for several indications and is currently being evaluated in Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

MV-NIS works through a sophisticated “search, destroy, and report” mechanism that leverages the natural biology of the measles virus.

1. Selective Targeting (The “Search”)

The measles vaccine strain used in this therapy naturally binds to a protein called CD46.

• Tumor Tropism: While CD46 is found on many cells, it is massively overexpressed on the surface of many cancer cells (like a “homing beacon”).
• Preferential Entry: The virus “ignores” healthy cells with low CD46 and focuses its entry on the malignant cells.

2. Direct Oncolysis (The “Destroy”)

Once inside the cancer cell, MV-NIS turns the cell into a “virus factory.”

• Viral Proliferation: The virus makes thousands of copies of itself.
• Cell Fusion (Syncytia): A unique feature of the measles virus is its ability to make neighboring cancer cells fuse together into large, multi-nucleated clumps called syncytia. This ensures that the infection spreads rapidly throughout the tumor mass.
• Rupture: Eventually, the fused cancer cells become unstable and burst (lyse), physically destroying the tumor.

3. The NIS Passenger Gene (The “Report”)

The virus carries the genetic code for the Thyroidal Sodium Iodide Symporter (NIS).

• Imaging: As the virus replicates, the cancer cell is forced to put NIS pumps on its surface. Doctors can then give the patient a tiny, safe dose of radioactive iodine (or technetium). The NIS pumps suck the radioactive tracer into the tumor, making it “light up” on a PET/SPECT scan. This tells the doctor exactly where the virus is working.
• Radiotherapy Enhancement: In some trials, a higher “therapeutic” dose of radioactive iodine (I-131) is given. The virus-infected cancer cells suck in the lethal radiation, providing a “second-hit” of treatment directly to the tumor from the inside.

Clinical Indications and Research Status (2026)

MV-NIS has been evaluated across several high-need oncology settings:

• Multiple Myeloma: This was the first major success for MV-NIS. A famous 2014 study showed a complete remission in a patient with widespread myeloma after a single high-dose IV infusion. 2026 trials are exploring its use in patients whose myeloma has become resistant to modern drugs like daratumumab.
• Ovarian Cancer: Investigated via intraperitoneal (IP) administration to target tumors lining the abdominal cavity.
• Endometrial and Fallopian Tube Cancers: Evaluated for recurrent cases where surgery is not an option.
• Malignant Mesothelioma: Studied for its ability to clear tumor cells from the lining of the lungs.

Dosage and Administration Protocols

As an investigational drug, the administration of MV-NIS is strictly managed within clinical trials (such as the NCT02364713 study).

Clinical Efficacy and Research Results (2024–2026)

Recent data has highlighted the “durable” nature of the immune response triggered by MV-NIS:

• Immune Conversion: Research in late 2025 showed that MV-NIS can turn “cold” (immune-invisible) tumors “hot.” By rupturing the cancer cells, the virus releases tumor antigens that “train” the patient’s own T-cells to recognize and attack the cancer.
• Synergy with Immunotherapy: 2026 trials are combining MV-NIS with checkpoint inhibitors (like pembrolizumab). The virus “breaks down the door” of the tumor, and the immunotherapy keeps the immune system attacking until the cancer is gone.

Safety Profile and Side Effects

The side effects of MV-NIS are mostly the result of a temporary, mild viral infection.

Common Side Effects (>50%):

• Flu-like Symptoms: Fever, chills, headache, and muscle aches. These are most common during the first 24–48 hours after treatment.
• Fatigue: General systemic tiredness.
• Nausea: Usually mild and well-controlled with standard medications.

Serious Risks:

• Measles Infection: While the virus is attenuated (weakened), there is a theoretical risk in severely immunocompromised patients; however, clinical data in 2025 has shown the virus to be exceptionally safe.
• Thrombocytopenia: A temporary drop in blood platelets was noted in some high-dose myeloma trials.
• Abdominal Pain: Common in intraperitoneal administration for ovarian cancer.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, MV-NIS is being used to study “Oncolytic Stem Cell Targeting.” Researchers are investigating how the virus can find and destroy “quiescent” (sleeping) cancer stem cells that are normally resistant to chemotherapy. In 2026, there is also intense focus on “MV-NIS Nanoparticles.” Scientists are developing ways to “cloak” the virus in a protective shell so that the patient’s own measles antibodies (from childhood vaccinations) don’t destroy the virus before it can reach the tumor.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Measles Antibody Testing: Patients are often screened to see if they have high levels of existing measles antibodies, which might neutralize the treatment.
• Baseline Blood Work: Comprehensive CBC and metabolic panel.

“Do’s and Don’ts” List:

• DO expect to have “flu-like” symptoms for a day or two; staying hydrated and resting is essential.
• DO attend your scheduled imaging scans (PET/SPECT) after the infusion; these are critical for the doctor to see if the virus has “taken” in the tumor.
• DON’T take high-dose steroids (like Prednisone) immediately before or after the treatment unless directed, as they can “dampen” the immune system and prevent the virus from working.
• DON’T worry about “infecting” others with measles; the virus used is highly modified and not “contagious” like the wild-type measles.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Oncolytic Measles Virus Encoding NIS is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.